Acadia Pharmaceuticals Inc. (ACAD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Acadia Pharmaceuticals Inc. (ACAD)
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Key Insights
Critical company metrics and information
Share Price
$17.17Market Cap
$2.86 BillionTotal Outstanding Shares
166.39 Million SharesTotal Employees
620Dividend
No dividendIPO Date
May 27, 2004SIC Description
Pharmaceutical PreparationsHomepage
https://www.acadia.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $10.31 Million |
Net Cash Flow From Investing Activities, Continuing | $-153.03 Million |
Net Cash Flow From Investing Activities | $-153.03 Million |
Net Cash Flow From Operating Activities, Continuing | $202.73 Million |
Net Cash Flow, Continuing | $60.00 Million |
Net Cash Flow From Operating Activities | $202.73 Million |
Net Cash Flow From Financing Activities | $10.31 Million |
Net Cash Flow | $60.00 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $0.78 |
Income/Loss From Continuing Operations Before Tax | $328.03 Million |
Net Income/Loss Available To Common Stockholders, Basic | $128.51 Million |
Basic Average Shares | $2.12 Million |
Revenues | $929.24 Million |
Net Income/Loss Attributable To Parent | $128.51 Million |
Net Income/Loss | $128.51 Million |
Diluted Average Shares | $2.81 Million |
Basic Earnings Per Share | $0.78 |
Income/Loss From Continuing Operations After Tax | $128.51 Million |
Income Tax Expense/Benefit | $8.19 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Gross Profit | $851.31 Million |
Benefits Costs and Expenses | $601.21 Million |
Operating Income/Loss | $112.23 Million |
Operating Expenses | $739.07 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Cost Of Revenue | $77.93 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Research and Development | $269.26 Million |
Selling, General, and Administrative Expenses | $469.81 Million |
Costs And Expenses | $620.90 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $788.28 Million |
Prepaid Expenses | $51.55 Million |
Equity | $577.18 Million |
Inventory | $86.74 Million |
Wages | $37.02 Million |
Equity Attributable To Parent | $577.18 Million |
Noncurrent Liabilities | $55.74 Million |
Assets | $976.87 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $19.08 Million |
Noncurrent Assets | $188.58 Million |
Liabilities And Equity | $976.87 Million |
Other Current Liabilities | $287.84 Million |
Fixed Assets | $3.99 Million |
Current Liabilities | $343.94 Million |
Other Current Assets | $649.99 Million |
Liabilities | $399.69 Million |
Other Non-current Assets | $184.60 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.